Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

miR-518f-5p decreases tetraspanin CD9 protein levels and differentially affects non-tumourigenic prostate and prostate cancer cell migration and adhesion.

Bond DR, Naudin C, Carroll AP, Goldie BJ, Brzozowski JS, Jankowski HM, Cairns MJ, Ashman LK, Scarlett CJ, Weidenhofer J.

Oncotarget. 2017 Dec 7;9(2):1980-1991. doi: 10.18632/oncotarget.23118. eCollection 2018 Jan 5.

2.

Characterization of the early molecular changes in the glomeruli of Cd151 -/- mice highlights induction of mindin and MMP-10.

Naudin C, Smith B, Bond DR, Dun MD, Scott RJ, Ashman LK, Weidenhofer J, Roselli S.

Sci Rep. 2017 Nov 22;7(1):15987. doi: 10.1038/s41598-017-15993-3.

3.

Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.

Smith AM, Dun MD, Lee EM, Harrison C, Kahl R, Flanagan H, Panicker N, Mashkani B, Don AS, Morris J, Toop H, Lock RB, Powell JA, Thomas D, Guthridge MA, Moore A, Ashman LK, Skelding KA, Enjeti A, Verrills NM.

Oncotarget. 2016 Jul 26;7(30):47465-47478. doi: 10.18632/oncotarget.10167.

4.

FMS-like tyrosine kinase 3 (FLT3) inhibitors: Molecular docking and experimental studies.

Mashkani B, Tanipour MH, Saadatmandzadeh M, Ashman LK, Griffith R.

Eur J Pharmacol. 2016 Apr 5;776:156-66. doi: 10.1016/j.ejphar.2016.02.048. Epub 2016 Feb 16.

PMID:
26896780
5.

Deletion of Cd151 reduces mammary tumorigenesis in the MMTV/PyMT mouse model.

Roselli S, Kahl RG, Copeland BT, Naylor MJ, Weidenhofer J, Muller WJ, Ashman LK.

BMC Cancer. 2014 Jul 11;14:509. doi: 10.1186/1471-2407-14-509.

6.

Knockout of the tetraspanin Cd9 in the TRAMP model of de novo prostate cancer increases spontaneous metastases in an organ-specific manner.

Copeland BT, Bowman MJ, Boucheix C, Ashman LK.

Int J Cancer. 2013 Oct 15;133(8):1803-12. doi: 10.1002/ijc.28204. Epub 2013 May 15.

7.

Renal disease as a potential compounding factor in carcinogenesis experiments with Cd151-null mice.

Ashman LK.

Oncogene. 2013 Sep 12;32(37):4457. doi: 10.1038/onc.2013.73. Epub 2013 Mar 11. No abstract available.

PMID:
23474759
8.

Expression of biologically active human colony stimulating factor-1 in Pichia pastoris.

Mashkani B, Odell AF, Byrnes EM, Griffith R, Ashman LK.

Protein Expr Purif. 2013 Mar;88(1):93-7. doi: 10.1016/j.pep.2012.11.017. Epub 2012 Dec 12.

PMID:
23246714
9.

Genetic ablation of the tetraspanin CD151 reduces spontaneous metastatic spread of prostate cancer in the TRAMP model.

Copeland BT, Bowman MJ, Ashman LK.

Mol Cancer Res. 2013 Jan;11(1):95-105. doi: 10.1158/1541-7786.MCR-12-0468. Epub 2012 Nov 6.

10.

Therapeutic targeting of c-KIT in cancer.

Ashman LK, Griffith R.

Expert Opin Investig Drugs. 2013 Jan;22(1):103-15. doi: 10.1517/13543784.2013.740010. Epub 2012 Nov 6. Review.

PMID:
23127174
11.

Cell line models identify different sensitivity of mutant forms of c-KIT to kinase inhibitory drugs and predict the response of patients to therapy.

Ashman LK.

Mol Cancer Ther. 2011 Nov;10(11):2032-3. doi: 10.1158/1535-7163.MCT-11-0706. No abstract available.

12.

The migration and invasion of human prostate cancer cell lines involves CD151 expression.

Ang J, Fang BL, Ashman LK, Frauman AG.

Oncol Rep. 2010 Dec;24(6):1593-7.

PMID:
21042756
13.

Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.

Roberts KG, Smith AM, McDougall F, Carpenter H, Horan M, Neviani P, Powell JA, Thomas D, Guthridge MA, Perrotti D, Sim AT, Ashman LK, Verrills NM.

Cancer Res. 2010 Jul 1;70(13):5438-47. doi: 10.1158/0008-5472.CAN-09-2544. Epub 2010 Jun 15.

14.

Colony stimulating factor-1 receptor as a target for small molecule inhibitors.

Mashkani B, Griffith R, Ashman LK.

Bioorg Med Chem. 2010 Mar 1;18(5):1789-97. doi: 10.1016/j.bmc.2010.01.056. Epub 2010 Jan 28.

PMID:
20156689
15.

A platelet tetraspanin superfamily member, CD151, is required for regulation of thrombus growth and stability in vivo.

Orlowski E, Chand R, Yip J, Wong C, Goschnick MW, Wright MD, Ashman LK, Jackson DE.

J Thromb Haemost. 2009 Dec;7(12):2074-84. doi: 10.1111/j.1538-7836.2009.03612.x. Epub 2009 Sep 9.

16.

Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.

Foster R, Byrnes E, Meldrum C, Griffith R, Ross G, Upjohn E, Braue A, Scott R, Varigos G, Ferrao P, Ashman LK.

Br J Dermatol. 2008 Nov;159(5):1160-9. doi: 10.1111/j.1365-2133.2008.08827.x. Epub 2008 Sep 15.

PMID:
18795925
17.

Identification of Tspan9 as a novel platelet tetraspanin and the collagen receptor GPVI as a component of tetraspanin microdomains.

Protty MB, Watkins NA, Colombo D, Thomas SG, Heath VL, Herbert JM, Bicknell R, Senis YA, Ashman LK, Berditchevski F, Ouwehand WH, Watson SP, Tomlinson MG.

Biochem J. 2009 Jan 1;417(1):391-400. doi: 10.1042/BJ20081126.

18.

Deletion of CD151 results in a strain-dependent glomerular disease due to severe alterations of the glomerular basement membrane.

Baleato RM, Guthrie PL, Gubler MC, Ashman LK, Roselli S.

Am J Pathol. 2008 Oct;173(4):927-37. doi: 10.2353/ajpath.2008.071149. Epub 2008 Sep 11.

19.

Probing the interaction of tetraspanin CD151 with integrin alpha 3 beta 1 using a panel of monoclonal antibodies with distinct reactivities toward the CD151-integrin alpha 3 beta 1 complex.

Yamada M, Tamura Y, Sanzen N, Sato-Nishiuchi R, Hasegawa H, Ashman LK, Rubinstein E, Yáñez-Mó M, Sánchez-Madrid F, Sekiguchi K.

Biochem J. 2008 Nov 1;415(3):417-27. doi: 10.1042/BJ20071625.

PMID:
18601653
20.

The role of the tetraspanin CD151 in primary keratinocyte and fibroblast functions: implications for wound healing.

Geary SM, Cowin AJ, Copeland B, Baleato RM, Miyazaki K, Ashman LK.

Exp Cell Res. 2008 Jul 1;314(11-12):2165-75. doi: 10.1016/j.yexcr.2008.04.011. Epub 2008 May 3.

PMID:
18534576
21.

Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor.

Young SM, Cambareri AC, Odell A, Geary SM, Ashman LK.

Cell Signal. 2007 Dec;19(12):2572-81. Epub 2007 Aug 15.

PMID:
17855052
22.

Resistance to c-KIT kinase inhibitors conferred by V654A mutation.

Roberts KG, Odell AF, Byrnes EM, Baleato RM, Griffith R, Lyons AB, Ashman LK.

Mol Cancer Ther. 2007 Mar;6(3):1159-66.

23.

Small molecule inhibitors of protein kinases in cancer- how to overcome resistance.

Griffith R, Brown MN, McCluskey A, Ashman LK.

Mini Rev Med Chem. 2006 Oct;6(10):1101-10. Review.

PMID:
17073710
24.

A critical role for tetraspanin CD151 in alpha3beta1 and alpha6beta4 integrin-dependent tumor cell functions on laminin-5.

Winterwood NE, Varzavand A, Meland MN, Ashman LK, Stipp CS.

Mol Biol Cell. 2006 Jun;17(6):2707-21. Epub 2006 Mar 29.

25.

Wound healing is defective in mice lacking tetraspanin CD151.

Cowin AJ, Adams D, Geary SM, Wright MD, Jones JC, Ashman LK.

J Invest Dermatol. 2006 Mar;126(3):680-9.

26.

An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development.

Cullinane C, Dorow DS, Kansara M, Conus N, Binns D, Hicks RJ, Ashman LK, McArthur GA, Thomas DM.

Cancer Res. 2005 Nov 1;65(21):9633-6.

27.
28.
29.

Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility.

Gesierich S, Paret C, Hildebrand D, Weitz J, Zgraggen K, Schmitz-Winnenthal FH, Horejsi V, Yoshie O, Herlyn D, Ashman LK, Zöller M.

Clin Cancer Res. 2005 Apr 15;11(8):2840-52.

30.

CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator?

Ang J, Lijovic M, Ashman LK, Kan K, Frauman AG.

Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1717-21. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):553.

31.

The tetraspanin superfamily member CD151 regulates outside-in integrin alphaIIbbeta3 signaling and platelet function.

Lau LM, Wee JL, Wright MD, Moseley GW, Hogarth PM, Ashman LK, Jackson DE.

Blood. 2004 Oct 15;104(8):2368-75. Epub 2004 Jun 29. Erratum in: Blood. 2005 Feb 15;105(4):1395.

PMID:
15226180
32.

Characterization of mice lacking the tetraspanin superfamily member CD151.

Wright MD, Geary SM, Fitter S, Moseley GW, Lau LM, Sheng KC, Apostolopoulos V, Stanley EG, Jackson DE, Ashman LK.

Mol Cell Biol. 2004 Jul;24(13):5978-88.

33.

alpha3beta1 integrin-CD151, a component of the cadherin-catenin complex, regulates PTPmu expression and cell-cell adhesion.

Chattopadhyay N, Wang Z, Ashman LK, Brady-Kalnay SM, Kreidberg JA.

J Cell Biol. 2003 Dec 22;163(6):1351-62.

34.

Physical proximity and functional interplay of PECAM-1 with the Fc receptor Fc gamma RIIa on the platelet plasma membrane.

Thai le M, Ashman LK, Harbour SN, Hogarth PM, Jackson DE.

Blood. 2003 Nov 15;102(10):3637-45. Epub 2003 Jul 31.

PMID:
12893767
35.

Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro.

Ferrao PT, Frost MJ, Siah SP, Ashman LK.

Blood. 2003 Dec 15;102(13):4499-503. Epub 2003 Jul 24.

PMID:
12881321
37.

Src family kinases are involved in the differential signaling from two splice forms of c-Kit.

Voytyuk O, Lennartsson J, Mogi A, Caruana G, Courtneidge S, Ashman LK, Rönnstrand L.

J Biol Chem. 2003 Mar 14;278(11):9159-66. Epub 2003 Jan 2.

39.

CD151.

Ashman LK.

J Biol Regul Homeost Agents. 2002 Jul-Sep;16(3):223-6. Review. No abstract available.

PMID:
12456024
40.

KIT gene mutations in gastrointestinal stromal tumors: more complex than previously recognized?

Fletcher JA, Fletcher CD, Rubin BP, Ashman LK, Corless CL, Heinrich MC.

Am J Pathol. 2002 Aug;161(2):737-8; author reply 738-9. No abstract available.

41.

Differential tissue expression of epitopes of the tetraspanin CD151 recognised by monoclonal antibodies.

Geary SM, Cambareri AC, Sincock PM, Fitter S, Ashman LK.

Tissue Antigens. 2001 Sep;58(3):141-53.

PMID:
11703821
42.

Effects of mutant c-kit in early myeloid cells.

Ashman LK, Ferrao P, Cole SR, Cambareri AC.

Leuk Lymphoma. 2000 Mar;37(1-2):233-43.

PMID:
10721793
43.

The biology of stem cell factor and its receptor C-kit.

Ashman LK.

Int J Biochem Cell Biol. 1999 Oct;31(10):1037-51. Review.

PMID:
10582338
44.

Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts.

Caruana G, Cambareri AC, Ashman LK.

Oncogene. 1999 Sep 30;18(40):5573-81.

45.

Effects of mutant c-Kit in early myeloid cells.

Ashman LK, Ferrao P, Cole SR, Cambareri AC.

Leuk Lymphoma. 1999 Aug;34(5-6):451-61. Review. Corrected and republished in: Leuk Lymphoma. 2000 Mar;37(1-2):233-43.

PMID:
10492068
46.
49.

Downregulation of c-kit (stem cell factor receptor) in transformed hematopoietic precursor cells by stroma cells.

Heberlein C, Friel J, Laker C, von Laer D, Bergholz U, Bögel M, Ashman LK, Klingler K, Ostertag W.

Blood. 1999 Jan 15;93(2):554-63.

PMID:
9885216
50.

Regulation of endothelial cell motility by complexes of tetraspan molecules CD81/TAPA-1 and CD151/PETA-3 with alpha3 beta1 integrin localized at endothelial lateral junctions.

Yáñez-Mó M, Alfranca A, Cabañas C, Marazuela M, Tejedor R, Ursa MA, Ashman LK, de Landázuri MO, Sánchez-Madrid F.

J Cell Biol. 1998 May 4;141(3):791-804.

Supplemental Content

Loading ...
Support Center